CompletedNot Applicable

Induction Related BK Viremia in Renal Transplant Patients

United States60 participantsStarted 2007-10

Plain-language summary

The increase immunosuppression in our transplant population has led to an unacceptable rate of patients at risk for BK virus nephropathy. Reducing induction immunosuppression by switching from Thymoglobulin to Simulect will reduce the incidence of serum positivity for BK by PCR.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * De novo transplant * Aged 18-75 Exclusion Criteria: * Serious medical condition which, in the opinion of the Principal Investigator, might interfere with the subject's ability to successfully complete the protocol. * Any medical condition which, in the opinion of the Principal Investigator, might compromise the safety of the subject in participating in the protocol

What they're measuring

BK Virus Viremia titer, >400 copies by Polymerase Chain Reaction (PCR)

Timeframe: One year

Trial details

NCT IDNCT00610961

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-04

View on ClinicalTrials.gov More Disease Due to BK Polyomavirus trials